Compare Intuitive Surgical, Inc. (ISRG) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? Intuitive Surgical, Inc. trades at $423.15 (market cap $149.10B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.78 (market cap $6.35B). The key difference: Intuitive Surgical, Inc. is far larger — about 23.5× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 9.8% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| ISRG | OWL | |
|---|---|---|
Market Cap | $149.10B | $6.35B |
Volume | 1,732,647 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $592.85 | $17.17 |
52-Week Low | $332.02 | $8.23 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $143.89B | $10.53B |
Dividend Yield | — | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $420.24, down 1.73% on the day, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The company reported $10.06B in 2025 revenue with 28.45% net margins, while technical indicators show a bullish trend with support at $414. Recent news highlights international expansion in India and Japan to offset China weakness.
ISRG presents a compelling investment case with 70% analyst buy ratings and a $480.78 price target offering 14% upside. Key risks include competitive pressures in robotic surgery and procedure growth concerns, but the company's market leadership and recurring revenue model support long-term growth prospects.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
